Your browser version may not work well with NCBI's Web applications. More information here...
1: Rev Med Interne. 2008 Sep;29(9):744-7. Epub 2008 Aug 3.Click here to read Links

[Cutaneous lupus induced by etanercept in rheumatoid arthritis]

[Article in French]

Abourazzak FE, Guggenbuhl P, Perdriger A, Meadeb J, Gando-Cocley N, Chevrant-Breton J, Hajjaj-Hassouni N, Chalès G.

Service de rhumatologie, hôpital El-Ayachi, CHU de Rabat-Salé, 10000 Rabat-Salé, Maroc. abourazakf@yahoo.fr

Therapy with anti-TNFalpha in rheumatoid arthritis may induce autoimmune disorders. Induction of autoantibodies is frequently observed, but lupus-like syndrome is rare and few cases only have been reported. We report a 41-year-old female, treated with etanercept for a rheumatoid arthritis, who developed a cutaneous lupus induced without any other organ involvement, associated with high ANA and DNA antibody titres. The skin biopsy and the histological analysis with immunofluorescence confirmed the diagnosis. The anti-TNFalpha treatment was stopped. Corticosteroids were increased and hydroxychloroquine administered because skin lesions persist after three months.

PMID: 18676065 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Abatacept (Orencia, Humira, Amevive, ...)

    How do targeted immune modulators compare in treating rheumatoid arthritis?

  • Hydroxychloroquine (Plaquenil® )

    Hydroxychloroquine is in a class of drugs called antimalarials. It is used to prevent and treat acute attacks of malaria. It is also used to treat discoid or systemic lupus erythematosus and rheumatoid arthritis in patie...

  • Source: AHFS Consumer Medication Information